EP0503055A1 - Inhibitor der lymphozyten-antwort und immunverwandter krankheiten - Google Patents
Inhibitor der lymphozyten-antwort und immunverwandter krankheitenInfo
- Publication number
- EP0503055A1 EP0503055A1 EP91918631A EP91918631A EP0503055A1 EP 0503055 A1 EP0503055 A1 EP 0503055A1 EP 91918631 A EP91918631 A EP 91918631A EP 91918631 A EP91918631 A EP 91918631A EP 0503055 A1 EP0503055 A1 EP 0503055A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- peptide
- amino acid
- peptide according
- cell
- proliferative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 201000010099 disease Diseases 0.000 title description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 31
- 230000004044 response Effects 0.000 title description 13
- 210000004698 lymphocyte Anatomy 0.000 title description 6
- 239000003112 inhibitor Substances 0.000 title description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 268
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 132
- 150000001413 amino acids Chemical class 0.000 claims abstract description 46
- 239000000427 antigen Substances 0.000 claims abstract description 40
- 108091007433 antigens Proteins 0.000 claims abstract description 39
- 102000036639 antigens Human genes 0.000 claims abstract description 39
- 235000001014 amino acid Nutrition 0.000 claims abstract description 36
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 32
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 32
- 235000018102 proteins Nutrition 0.000 claims abstract description 31
- 238000006467 substitution reaction Methods 0.000 claims abstract description 13
- 210000000056 organ Anatomy 0.000 claims abstract description 10
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims abstract description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 10
- 230000002401 inhibitory effect Effects 0.000 claims description 30
- 230000002062 proliferating effect Effects 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 18
- 230000001363 autoimmune Effects 0.000 claims description 12
- 241000186359 Mycobacterium Species 0.000 claims description 7
- 241000700199 Cavia porcellus Species 0.000 claims description 6
- 102000006386 Myelin Proteins Human genes 0.000 claims description 5
- 108010083674 Myelin Proteins Proteins 0.000 claims description 5
- 210000005012 myelin Anatomy 0.000 claims description 5
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 63
- 102000002812 Heat-Shock Proteins Human genes 0.000 abstract description 21
- 108010004889 Heat-Shock Proteins Proteins 0.000 abstract description 21
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract description 14
- 235000004279 alanine Nutrition 0.000 abstract description 14
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 8
- 230000002265 prevention Effects 0.000 abstract description 3
- 206010071155 Autoimmune arthritis Diseases 0.000 abstract description 2
- 208000026278 immune system disease Diseases 0.000 abstract 2
- 206010003246 arthritis Diseases 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 36
- 241000700159 Rattus Species 0.000 description 34
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 31
- 102000047918 Myelin Basic Human genes 0.000 description 29
- 101710107068 Myelin basic protein Proteins 0.000 description 29
- 238000002649 immunization Methods 0.000 description 26
- 238000000338 in vitro Methods 0.000 description 20
- 230000003053 immunization Effects 0.000 description 19
- 230000006698 induction Effects 0.000 description 19
- 230000005764 inhibitory process Effects 0.000 description 19
- 230000004936 stimulating effect Effects 0.000 description 18
- 230000009696 proliferative response Effects 0.000 description 17
- 210000001165 lymph node Anatomy 0.000 description 15
- 208000009386 Experimental Arthritis Diseases 0.000 description 13
- 239000002671 adjuvant Substances 0.000 description 13
- 108091008874 T cell receptors Proteins 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 11
- 230000001939 inductive effect Effects 0.000 description 9
- 230000003286 arthritogenic effect Effects 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 201000008827 tuberculosis Diseases 0.000 description 8
- 208000023275 Autoimmune disease Diseases 0.000 description 7
- 230000002860 competitive effect Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 6
- 230000009257 reactivity Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 230000005784 autoimmunity Effects 0.000 description 5
- -1 hsp 65 Proteins 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 230000000069 prophylactic effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 101710122462 65 kDa protein Proteins 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 101001018322 Sus scrofa Myelin basic protein Proteins 0.000 description 4
- 230000006052 T cell proliferation Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000001712 encephalitogenic effect Effects 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 238000011694 lewis rat Methods 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- ZLDPNFYTUDQDMJ-UHFFFAOYSA-N n-octadecyloctadecan-1-amine;hydrobromide Chemical compound Br.CCCCCCCCCCCCCCCCCCNCCCCCCCCCCCCCCCCCC ZLDPNFYTUDQDMJ-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000011533 pre-incubation Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010003267 Arthritis reactive Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 3
- 108010062580 Concanavalin A Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 102000016611 Proteoglycans Human genes 0.000 description 3
- 108010067787 Proteoglycans Proteins 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 230000030741 antigen processing and presentation Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000019069 chronic childhood arthritis Diseases 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 208000002574 reactive arthritis Diseases 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 241000187644 Mycobacterium vaccae Species 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000607734 Yersinia <bacteria> Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006957 competitive inhibition Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- HICVMZCGVFKTPM-BQBZGAKWSA-N Asp-Pro-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O HICVMZCGVFKTPM-BQBZGAKWSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 101100327692 Caenorhabditis elegans hsp-60 gene Proteins 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101500024558 Homo sapiens Pancreatic icosapeptide Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102400000108 N-terminal peptide Human genes 0.000 description 1
- 101800000597 N-terminal peptide Proteins 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 230000037453 T cell priming Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003277 amino group Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000027906 leg weakness Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention in the field of immunology and medicine relates to peptides which mimic a natural peptide and compete with the heat shock protein, hsp 65, or peptides derived therefrom for recognition by and activation of T lymphocytes.
- the peptides of the invention inhibit T lymphocyte activation and proliferative responses, and can protect a subject from immune reactions and immune-related disease including autoimmunity and graft rejection.
- autoimmune diseases are both long and disturbing. It includes, for example, multiple sclerosis, myasthenia gravis, rheumatoid arthritis, and systemic lupus erythematosus. In all of these diseases, the immune response is potent and specific. The problem is that this immune response is directed at some essential component of the body. Millions of people are afflicted with chronic forms of arthritis which are thought to involve autoimmunity to constituents of the joints of connecting tissues of the body. These conditions include rheumatoid arthritis, ankylo ⁇ ing ⁇ pondyliti ⁇ , Reiter' ⁇ syndrome, and other forms of reactive arthritis.
- Adjuvant arthritis is an experimental model of human arthritis inducible by immunizing susceptible strains of rats to Mvcobacteria.
- the disease which develops about twelve days after immunization has many of the features of rheumatoid arthritis, and, indeed, adjuvant arthritis has been considered to be a model for rheumatoid arthritis.
- Rats immunized with adjuvant containing mycobacterial antigens to produce arthritis contain T lymphocytes specific for mycobacterial antigens. Indeed, long term T cell lines and clones have been isolated from rats so immunized; these T cell were able to induce and modulate the arthritic disease in vivo (Holoshitz, Science, 1983, 219;56; Holoshitz, J. et al.. J. Clin. Invest. ,
- T cell clone designated A2b
- the minimal antigenic structure, or epitope, responsible for this mimicry between a cartilage-as ⁇ ociated self structure and mycobacteria, recognized by both of the above T cell clone ⁇ , is the amino acid ⁇ equence from residue 180 to 188 of the mycobacterial 65 kD heat-shock protein (HSP) (Van Eden, W. et al. , Nature 1988, 331:171) .
- HSP heat-shock protein
- HSPs Heat shock proteins
- HSPs serve as important antigens of infectiou ⁇ agents, and possibly,of transformed cells. During infection, HSP ⁇ are induced in both microorganisms and host phagocytes. The dominant antigens of intracellular pathogenic microorganisms are HSP ⁇ known as hsp 65 (the human representative of the hsp 60 family of molecules) and hsp 70. Due to their extreme conservation, it is not surprising that HSPs bear a relationship with autoimmune diseases. Cloned "autoreactive" T cells have been obtained from normal donors that are reactive to human h ⁇ p 65 and h ⁇ p 70. D. Immunity to Heat Shock Proteins in Arthritis
- Adjuvant arthriti ⁇ can be induced u ⁇ ing M ⁇ . tuberculosis in oil in Lewis rats and, to a les ⁇ er extent, in Fisher and BN rats.
- the expression of the mammalian homolog HSP is selectively enhanced in affected joint tissue of rats with adjuvant arthritis and patients with rheumatoid arthritis (Karlsson-Parra, A.K. et al. , Scand. J. Immunol. 3.1:283-288 (1990) ) .
- the inventors and their colleagues reported that the minimal stimulatory sequence for two arthritis-specific T lymphocyte clones, A2b and A2c, was defined as the 180-187 amino acids sequence of the mycobacterial hsp 65 (Van der Zee, R. et al. , Eur. J. Immunol. :43 (1989)). Peptides having any amino acid replacement at po ⁇ ition ⁇ 187 and 188 fully stimulated both T cell clones, indicating that these positions did not affect the antigenic nature of the 180-186 heptapeptide. It was thought that mimicry occurs with an hsp 65 epitope of a proteoglycan-associated HSP or an HSP expressed in synovial ti ⁇ sue ⁇ .
- a refractory state can be "artificially" induced in the Lewi ⁇ rat adjuvant arthriti ⁇ model by prior treatment wit soluble mycobacterial h ⁇ p 65, which al ⁇ o down-regulates responses to the nonapeptide; this treatment also prevents SCW-induced arthritis and partially inhibits collagen-induced arthriti ⁇ .
- T cell re ⁇ pon ⁇ e ⁇ to mycobacterial hsp 65 are elevated in the synovial fluid, compared with blood; T cells from a few JRA patients with elevated antibody respon ⁇ e ⁇ to hsp 65 responded to the 180-188 nonapeptide (Lydard, P.M. et al. , Immunol. Today 11:228 (1990)).
- Stanford et al. discloses aqueous acetone soluble and insoluble fractions of certain mycobacteria, such a ⁇ Mvcobacterium H-37, M. kansa ⁇ ii and M. vaccae.
- the soluble fraction of H-37 was found to provoke an immune re ⁇ ponse leading to resistance to adjuvant arthritis wherea ⁇ the in ⁇ oluble fraction seemed to be responsible for the induction of the disease.
- M. vaccae was shown to be substantially free of adjuvant arthritis-inducing components.
- One T cell line, de ⁇ ignated A2 was found to induce arthritis upon intravenous (IV) injection into irradiated rat ⁇ .
- the A2 cell ⁇ were effective in vaccinating unirradiated rat ⁇ again ⁇ t ⁇ ubsequent induction of arthritis by active immunization with mycobacteria.
- Cell line A2 was cloned, yielding two distinct clone ⁇ , designated A2b and A2c.
- A2b cells induce arthritis but do not vaccinate against arthritis.
- Clone A2c cell ⁇ do not cause arthritis, but rather vaccinate against it, and additionally can be used to treat existing adjuvant arthritis. Moreover, clones A2b and A2c are used to identify antigens associated with arthritogenicity or with suppression of arthritogenicity. Both clones respond in vitro to whole mycobacteria as well as to cartilage proteoglycan protein.
- Van Eden et al. European Patent Publication EP 262710 (4/6/88)
- a protein having an apparent molecular weight of about 64 kDa (the preparation of which is described in Thole, J.E.R. et al. , Infec. Immun. 50:800-806 (1985)) is useful as a vaccine for inducing resistance again ⁇ t autoimmune arthritis and similar autoimmune diseases.
- This publication also disclose ⁇ that this protein, also known a ⁇ antigen A, cross-reacted serologically with antigen ⁇ pre ⁇ ent in other bacterial ⁇ pecies, such as Mycobacteria.
- These polypeptides could be used as immunogens in pharmaceutical compositions, particularly a ⁇ vaccines, for the alleviation and the treatment of autoimmune disea ⁇ e ⁇ , a ⁇ well a ⁇ in diagnostic composition ⁇ for the diagnosis of these disease ⁇ .
- Thi ⁇ reference provided no guidance a ⁇ to which re ⁇ idue ⁇ could be ⁇ ub ⁇ tituted, and what amino acid ⁇ could serve a ⁇ appropriate ⁇ ubstitutes, in order to obtain a useful polypeptide for preventing or treating autoimmune disease.
- a peptide of at least seven amino acid residue ⁇ capable of inhibiting the proliferative response of a T lymphocyte to a specific antigen comprise ⁇ an amino acid sequence which corre ⁇ pond ⁇ to positions 180-186 of the Mycobacterium tuberculosis protein h ⁇ p 65 having the formula TFGLQLE but differing therefrom by one to three amino acid substitution ⁇ in the po ⁇ ition ⁇ 181-183, competes with hsp 65 for recognition by antigen reactive lymphocyte clones, such as clones A2b and A2c in experimental arthritis.
- These substitutions can be of any form wherein the modified hsp 65 180-186 ⁇ equence is recognized by antigen- reactive T lymphocytes, such as T lymphocytes reactive to M.
- tuberculosi ⁇ or any epitope thereof preferably to h ⁇ p 65, T lymphocyte ⁇ reactive to myelin ba ⁇ ic protein (MBP) , and the like, and the proliferative re ⁇ ponse of the T cell ⁇ is inhibited.
- MBP myelin ba ⁇ ic protein
- the present invention provides a peptide of at lea ⁇ t ⁇ even amino acid re ⁇ idue ⁇ capable of inhibiting the proliferative re ⁇ pon ⁇ e of a T lymphocyte to a specific antigen, said peptide comprising an amino acid sequence which corresponds to positions 180-186 of the Mycobacterium tuber ⁇ culosis protein hsp 65 having the formula:
- the peptide of the present invention has up to 20 amino acid residues, most preferably between 7 and 9 amino acid re ⁇ idue ⁇ .
- Preferred peptide of the pre ⁇ ent invention has the formula TFGAQLE, TFGAQLELT, TAGLQLE or TAGLQLELT.
- the above peptides are capable of inhibiting the proliferative response to hsp 65 of a T lymphocyte reactive thereto, a proliferative response to myelin basic protein of a T lymphocyte reactive thereto, or a proliferative response to Mycobacterium tuberculo ⁇ is of a T lymphocyte reactive thereto.
- the present invention i ⁇ further directed to a method for treating a ⁇ ubject having an autoimmune disease comprising administering to the subject an effective amount of a peptide of the present invention.
- the autoimmune di ⁇ ea ⁇ e i ⁇ arthritis In a preferred embodiment, the autoimmune di ⁇ ea ⁇ e i ⁇ arthritis.
- the present invention also provides a method for suppressing or preventing the rejection of a transplanted organ or tissue in a subject comprising administering to the subject an effective amount of a peptide according to the present invention, prior to and/or immediately after receipt of the transplanted organ or tis ⁇ ue.
- the pre ⁇ ent invention i ⁇ further directed to a T lymphocyte line or clone compri ⁇ ing T lymphocyte ⁇ ⁇ pecifically reactive to any of the peptide ⁇ of the pre ⁇ ent invention, and to the u ⁇ e of ⁇ uch cell ⁇ in the prevention or suppression of an immune-mediated disease, preferably arthritis.
- Figure 1 is a diagram showing two amino acid sub ⁇ titution networks for the nonapeptide comprising positions 180-188 of the mycobacterial 65 kD protein, hsp 65.
- Figure la pre ⁇ ents the "single substitution network," wherein every residue of the 180-188 sequence was replaced by each of 19 different amino acids.
- Figure lb presents the "combination network,” wherein substitution ⁇ at positions 180, 181, and 186 were combined.
- Figure 2 is a graph showing proliferative respon ⁇ es of the T cell clone, A2c, to the ⁇ timulatory h ⁇ p 65 180-188 peptide, and their inhibition by alanine-substituted peptides, where the competitive peptides were added prior to stimulation.
- Figure 3 is a graph showing rever ⁇ al of A183 inhibi ⁇ tion of T cell proliferation by increa ⁇ ing concentration ⁇ of peptide 180-188.
- Figure 4 i ⁇ a graph showing proliferative re ⁇ pon ⁇ es of the T cell clone, A2b, to the ⁇ timulatory hsp 65 180-188 peptide, and their inhibition by alanine-substituted peptides, where the competitive peptides were added at the time of stimulation.
- Figure 5 includes graphs showing results of experiments which demonstrate the dose dependency of the inhibitory activities of A183.
- Figure 6 is a graph showing that responses of an encephalitogenic T cell clone, Zla, specific for myelin basic protein, are inhibited by the A183 peptide.
- Figure 7 is a graph showing proliferative respon ⁇ e ⁇ to various doses of A183 of lymph node cells obtained from animals either immunized or not immunized with A183.
- Figure 8 is a graph showing that co-administration of A183 and an arthritogenic dose of Mycobacterium tuberculosi ⁇ reduces the severity of arthritis.
- Figure 9 is a graph showing the in vitro proliferative re ⁇ pon ⁇ es of clone A2b T cell ⁇ to single amino acid sub ⁇ titution variants of peptide 180-188.
- FIGS. 10 and Figure 11 are graphs showing proliferative responses of T cell clone A2b (Fig. 10) and T cell line Zla (Fig. 11) to single alanine sub ⁇ tituted variant peptides of peptide 180-188 corresponding to hsp 65 (for A2b) and of peptide 1020 corresponding to MBP (for Zla) .
- the peptide 180-188 comprise ⁇ wa ⁇ te ⁇ ted at concentration ⁇ of approximately 2-3 ⁇ g/ml, and the peptide 1020 series at concentrations of approximately 50 ⁇ g/ml.
- SI a ⁇ stimulation index
- Figure 12 and Figure 13 are graphs showing competition for antigen presentation between non-stimulatory single alanine ⁇ ub ⁇ tituted peptide analogue ⁇ and the unmodified 180-188 peptide.
- Non-stimulatory alanine ⁇ ub ⁇ tituted peptide analogue ⁇ of peptide 180-188 (Fig. 12) and peptide 1020 (Fig. 13) were preincubated with antigen presenting cells and A2b T cell ⁇ 2 h before the addition of the stimulatory peptide 180-188.
- Competition wa ⁇ asses ⁇ ed by determining the reduction of proliferation in the pre ⁇ ence of varying concentration ⁇ of the competitor peptide, ⁇ timulated by a suboptimal concentration of the stimulatory peptide 180- 188 (0.5 ⁇ g/ml) .
- Unstimulated control values were approximately 200 cpm. Results shown are the mean cpm of triplicate cultures. Error bars represent the ⁇ tandard error of the mean.
- Figure 14 is a graph showing the reduction of arthritis severity after disease induction with M. tuberculosis (Mt) when co-injected with peptide A183.
- the re ⁇ ults shown are the mean arthriti ⁇ ⁇ core ⁇ of each group. Error bar ⁇ represent the standard error of the mean.
- the pre ⁇ ent invention i ⁇ ba ⁇ ed on the unexpected di ⁇ covery by the inventors that peptide ⁇ at lea ⁇ t ⁇ even amino acid ⁇ , corresponding to a portion of the Mycobacterium tuberculosis hsp 65 protein, which have substituted amino acids in certain po ⁇ itions, but not in others, are potent generalized inhibitors of T lymphocyte proliferative re ⁇ ponse ⁇ as measured in vitro, and of immune-related diseases such a ⁇ autoimmune disea ⁇ e ⁇ in vivo.
- the peptide ⁇ of the pre ⁇ ent invention are those peptides which have at lea ⁇ t seven amino acid re ⁇ idues comprising an amino acid sequence which corresponds to positions 180-186 of the Mycobacterium tuberculosis protein hsp 65 having the formula: 180 186
- the peptide of the present invention has up to 20 amino acids, most preferably, between 7 and 9 amino acids.
- these peptide ⁇ are recognized by the immune system (either by T cell ⁇ or antigen-presenting cells) and are capable of inhibiting the proliferative re ⁇ pon ⁇ e of a T lymphocyte to an antigen to which the T lymphocyte is specific. Because of this recognition and inhibitory action, the peptides of the present invention can be used as com ⁇ petitors for recognition by any antigen-reactive T lymphocyte, or by an antigen-presenting cell. The peptide ⁇ inhibit the normal stimulation of such T lymphocytes and thereby protect - a subject from an immune-related disease, such as an autoimmune disea ⁇ e.
- ⁇ ub ⁇ titution of positions 181 and 183, most preferably position 183, of hsp 65, especially with alanine result ⁇ in a peptide having the de ⁇ ired propertie ⁇ a ⁇ taught herein, and u ⁇ eful for protection of a ⁇ ubject from an immune-related disea ⁇ e.
- a peptide of at lea ⁇ t ⁇ even amino acid residues comprising an amino acid sequence which correspond ⁇ to po ⁇ itions 72-85 of guinea pig yelin basic protein (MBP)
- a preferred peptide corresponding to the MBP sequence has the formula QKSQRSQAENPV. Identification of ⁇ ub ⁇ tituted peptide ⁇ which are useful in the methods of the pre ⁇ ent invention can be ea ⁇ ily accomplished by testing their ability to inhibit proliferative re ⁇ ponses in vitro of T cell ⁇ , a ⁇ exemplified by the arthritis-related rat T cell clone ⁇ A2b and A2c.
- immune-related di ⁇ ea ⁇ e a ⁇ u ⁇ ed herein refers to a disease in which the immune system is involved in the pathogenesi ⁇ of the disease, or in which appropriate stimulation of the immune system can result in protection from the di ⁇ ea ⁇ e.
- a preferred example of an immune-related disease to which this invention is directed is an autoimmune di ⁇ ea ⁇ e.
- Non-limiting example ⁇ of such autoimmune disea ⁇ e ⁇ are rheumatoid arthriti ⁇ , reactive arthritis, myasthenia gravis, multiple ⁇ clerosis, systemic lupus erythematosus, autoimmune thyroiditi ⁇ (Ha ⁇ himoto' ⁇ thyroiditi ⁇ ) , Graves' disea ⁇ e, inflammatory bowel di ⁇ ea ⁇ e, autoimmune uveoretiniti ⁇ , and polymyo ⁇ iti ⁇ .
- peptides are provided which can compete efficiently with Mycobacterium tuberculosis, the native Mycobacterium tuberculosis hsp 65 protein, , or its native peptide 180-188 for recognition by T lymphocyte ⁇ which are as ⁇ ociated with an immune-related disease, such as the arthriti ⁇ - ⁇ pecific T lymphocyte clone ⁇ , A2b and A2c.
- the peptide ⁇ compete with MBP for recognition by the MBP- ⁇ pecific and EAE-inducing T cell line, Zla.
- the peptide ⁇ of the pre ⁇ ent invention are ⁇ ub ⁇ tituted h ⁇ p 65 peptide ⁇ which can compete efficiently with the native h ⁇ p 65 peptide 180-188 for recognition by A2b and A2c T cell clone ⁇ , mea ⁇ ured a ⁇ inhibition of native hsp 65-induced, or native peptide 180-188-induced proliferation by the clones.
- a most preferred embodiment i ⁇ the 180-186 or
- A183 180-188 peptide of h ⁇ p 65 with alanine at po ⁇ ition 183 (A183) .
- A183 a particularly effective competitor for binding to the T cell, pre ⁇ umably to the T cell receptor (TCR) , the MHC molecule of the antigen-pre ⁇ enting cell, or both.
- TCR T cell receptor
- the A183 ⁇ ub ⁇ titution al ⁇ o creates a peptide particularly effective in inhibiting activation and proliferation of arthritis-specific T cells. Additionally, because of its immunogenicity (see Examples) , A183 can induce T cells specific for itself, which apparently counteract the deleterious autoimmune response in vivo.
- A183 is considered to be not merely a competitor peptide but a “competitor-modulator” peptide.
- arthriti ⁇ - ⁇ pecific T cell i ⁇ intended any T lymphocyte, T lymphocyte line or clone, which i ⁇ particularly associated with arthritis by virtue of the T cell's ability to induce arthriti ⁇ , vaccinate against arthriti ⁇ , or otherwi ⁇ e modulate the induction, maintenance, or suppre ⁇ sion of arthritis in a disease-specific manner.
- an arthritis ⁇ pecific T cell i ⁇ immunoreactive in vitro or in vivo with antigens such as M.
- tubercu1osis tubercu1osis, hsp 65, or any amino acid sequence in the hsp 65 protein which is a ⁇ ociated with arthriti ⁇ .
- Examples of sub ⁇ titution ⁇ re ⁇ ulting in T cell inhib ⁇ itory activity include tho ⁇ e in which alanine has been substi ⁇ tuted as follows:
- substitution ⁇ are preferably with amino acids similar to ala, that i ⁇ small aliphatic, nonpolar or slightly polar residue ⁇ : ⁇ er, thr, or gly. However, other amino acid ⁇ ub ⁇ titution ⁇ are not excluded.
- a “chemical derivative” of the peptide of the present invention contains additional chemical moieties not normally a part of the peptide. Covalent modifications of the peptide are included within the scope of thi ⁇ invention. Such modifications may be introduced into the molecule by reacting targeted amino acid residues of the peptide with an organic derivatizing agent that is capable of reacting with selected side chains or terminal residue ⁇ . Many such chemical derivatives and methods for making them are well-known in the art. See, for non-limiting examples, U.S.
- Salts of a carboxyl group may be formed by means known in the art and include inorganic ⁇ alt ⁇ , for example, sodium, calcium, ammonium, ferric or zinc salt ⁇ , and the like, and ⁇ alt ⁇ with organic ba ⁇ e ⁇ ⁇ uch a ⁇ tho ⁇ e formed for example, with a ine ⁇ , ⁇ uch a ⁇ triethanolamine, arginine, or ly ⁇ ine, piperidine, procaine, and the like.
- Acid addition ⁇ alts include, for example, salt ⁇ with mineral acid ⁇ ⁇ uch a ⁇ , for example, hydrochloric acid or ⁇ ulfuric acid, and ⁇ alts with organic acids ⁇ uch a ⁇ , for example, acetic acid or oxalic acid.
- Al ⁇ o included within the ⁇ cope of the pre ⁇ ent invention are the peptides described herein attached to various carriers or immobilized matrices, as is well-known in the art.
- enzymatic degradation of the peptide ⁇ of the pre ⁇ ent invention in vivo may cau ⁇ e the peptide ⁇ to be relatively short-lived.
- One method of preventing such degradation would be by making synthetic peptides containing a D-amino acid.
- peptide by moieties intended to affect solubility, e.g, by the addition of a hydrophilic residue, such a ⁇ ⁇ erine, or a charged residue, such as glutamic acid.
- the peptide could be extended for the purpose of stabilization and preservation of a desired conformation, such as by adding cysteine re ⁇ idues for the formation of di ⁇ ulfide bridges.
- Another reason to modify the peptides would be to permit their detection after administration. This can be done by radioiodination with a radioactive iodine isotope, directly, or by adding tyrosine for ⁇ ubsequent radioiodination, as di ⁇ cussed above.
- an inhibitory peptide in accordance with the pre ⁇ ent invention i ⁇ that it be a ligand for the TCR and/or an MHC molecule such that the peptide is recognized by the T cell or antigen-presenting cell of interest, such a ⁇ the A2b and A2c clones, with sufficient affinity to compete successfully for binding with a native or other stimulatory protein or peptide (such as native h ⁇ p 65 or a ⁇ timulatory peptide derived therefrom) .
- a native or other stimulatory protein or peptide such as native h ⁇ p 65 or a ⁇ timulatory peptide derived therefrom
- the pre ⁇ ent invention provide ⁇ T lymphocyte ⁇ ⁇ pecific for the ⁇ e competitor-modulator peptides.
- An example of such an A183- ⁇ pecific T cell line similar in the rat is the ATL line described in Example XIV.
- Such cells are produced by appropriate immunization in vivo and restimulation in vitro, a ⁇ di ⁇ cussed below.
- Included within the scope of the present invention are human T cells specific for the peptides of the invention, preferably derived from the individual who will be the subject of the prevention or treatment of immune-related disea ⁇ e, ⁇ uch a ⁇ arthriti ⁇ .
- T cell lines are treated in a way which will permit their preventative or therapeutic efficacy, while inactivating them for any potential pathogenetic activity.
- Methods for inactivating cells or otherwi ⁇ e rendering them fit for vaccination again ⁇ t autoimmunity are well-known in the art, many of them having been developed by some of the present inventors.
- Such methods include treatment with hydrostatic pressure, with chemical cross-linking agents ⁇ uch a ⁇ glutaraldehyde, with a cyto ⁇ keletal di ⁇ rupting agent ⁇ uch a ⁇ cytochala ⁇ in B, or with low do ⁇ es of cells (U.S. Patents 4,634,590 and 4,716,038; Cohen, I.R. et al.
- the T cell ⁇ of the pre ⁇ ent invention are expected to induce regulatory anti-idiotypic or anti-clonotypic respon ⁇ e ⁇ directed again ⁇ t a ⁇ hared T cell receptor idiotope of the di ⁇ ease-inducing T cell ⁇ .
- a regulatory respon ⁇ e could prevent the development of the di ⁇ ea ⁇ e.
- Peptides according to the present invention are administered to patients having, or known to be susceptible to, an immune-related di ⁇ ea ⁇ e in amount ⁇ ⁇ ufficient to protect the patient from the disease by preventing the patient's immune system from activation leading to induction, maintenance or exacerbation of the disease state.
- the immune-related disea ⁇ es contemplated within the scope of the pre ⁇ ent invention are al ⁇ o di ⁇ ea ⁇ e ⁇ involving graft rejection or graft-ver ⁇ u ⁇ -ho ⁇ t di ⁇ ea ⁇ e.
- the peptides of the present invention are administered to organ transplant recipients- prior to receipt of the transplanted organ, immediately after receipt of the tran ⁇ planted organ, or both, in order to ⁇ uppre ⁇ s or prevent rejection of the tran ⁇ planted organ.
- the term "immediately after” as used herein i ⁇ intended to include administration beginning in the first few hours po ⁇ t-tran ⁇ plant. However the term i ⁇ not intended to limit the duration of treatment po ⁇ t-tran ⁇ plant, which can be readily determined by one of ⁇ kill in the art can without undue experimentation.
- T lymphocyte ⁇ which recognize foreign hi ⁇ tocompatibility antigens are transferred from donor to recipient and react against the recipient leading to a variety of inflammatory con ⁇ equences which may lead to significant morbidity and even mortality (See, for example, Roitt, I. et al. , Immunology, The C.V. Mosby Company, Gower Medical Publishing, London, 1985) .
- the peptides of the present invention are administered to an individual su ⁇ ceptible to a graft-ver ⁇ u ⁇ -ho ⁇ t reaction, ⁇ uch a ⁇ a bone marrow tran ⁇ plant recipient or a susceptible pregnant woman, to prevent the recognition of foreign cells i the "host" by the graft, thereby treating a graft-versu ⁇ -ho ⁇ t reaction.
- the dose ranges for the administration of the composition ⁇ of the pre ⁇ ent invention are those large enough to produce the desired effect, whereby, for example, an immune respon ⁇ e to a ⁇ timulatory peptide, as measured by T cell proliferation in vitro or a delayed hypersensitivity response in vivo, is sub ⁇ tantially prevented or inhibited, and further, where the immune-related disease is significantly treated.
- the dose ⁇ should not be so large as to cau ⁇ e adverse side effects, such as unwanted cros ⁇ reactions, generalized immunosuppre ⁇ ion, anaphylactic reaction ⁇ and the like.
- Effective do ⁇ e ⁇ of the peptides of this invention for use in treating an immune-related disea ⁇ e are in the range of about 1 ng to 100 mg/kg body weight.
- a preferred dose range i ⁇ between about 10 ng and 10 mg/kg.
- a more preferred dose range i ⁇ between about 100 ng and 1 mg/kg.
- the effective T lymphocyte do ⁇ e i ⁇ a function of the individual T cell line, the ⁇ ubject and hi ⁇ clinical ⁇ tatus, and can vary from about 10 6 to about 10 9 cell ⁇ /kg body weight.
- the dosage administered will be dependent upon the age, ⁇ ex, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
- the route of administration may include intravenous, ⁇ ubcutaneous, intraarticular, intramuscular, by inhalation, intraperitoneal, intranasal, intrathecal, intradermal, trans- dermal or other known routes, including the enteral route.
- composition ⁇ may contain ⁇ uitable pharmaceutically acceptable carrier ⁇ comprising excipients and auxiliaries which facilitate proces ⁇ ing of the active compound ⁇ into preparation ⁇ which can be u ⁇ ed pharmaceutically.
- the pharmaceutical compo ⁇ ition ⁇ of the invention may be admini ⁇ tered to any animal which may experience the beneficial effect ⁇ of the compo ⁇ ition ⁇ of the invention.
- Foremo ⁇ t among ⁇ uch animal ⁇ are human ⁇ , although the invention i ⁇ not intended to be ⁇ o limited.
- compositions of the present invention may be administered by any means that achieve their intended purpose, for example, by the routes described above. Alternatively, or concurrently, administration may be by the oral route.
- the peptides, T cell ⁇ and pharmaceutical compo ⁇ ition ⁇ can be administered parenterally by bolus injection or by gradual perfusion over time.
- the peptide ⁇ can be incorporated into lipo ⁇ omes using methods and compounds known in the art.
- Preparation ⁇ which can be administered orally in the form of tablets and capsules, preparations which can be ad ⁇ ministered rectally, such as suppositorie ⁇ , and preparation ⁇ in the form of solutions for injection or oral introduction, contain from about 0.001 to about 99 percent, preferably from about 0.01 to about 95 percent of active compound(s) , together with the excipient.
- Suitable excipients are, in particular, fillers such a ⁇ ⁇ accharides, for example lactose or ⁇ ucro ⁇ e, mannitol or sorbitol, cellulose preparations and/or calcium pho ⁇ phate ⁇ , for example tricalcium pho ⁇ phate or calcium hydrogen pho ⁇ - phate, a ⁇ well a ⁇ binder ⁇ ⁇ uch as starch paste, using, for example, maize ⁇ tarch, wheat ⁇ tarch, rice starch, potato ⁇ tarch, gelatin, tragacanth, methyl cellulose, hydroxy- propylmethylcellulo ⁇ e, ⁇ odium carboxymethylcellulo ⁇ e, and/or polyvinyl pyrrolidone.
- fillers such a ⁇ ⁇ accharides, for example lactose or ⁇ ucro ⁇ e, mannitol or sorbitol, cellulose preparations and/or calcium pho ⁇ phate ⁇ , for example tricalcium pho ⁇ phat
- compositions which can be used orally include push-fit capsules made of gelatin, a ⁇ well a ⁇ soft, sealed capsule ⁇ made of gelatin and a plasticizer such a ⁇ glycerol or sorbitol.
- the pu ⁇ h-fit cap ⁇ ule ⁇ can contain the active compound ⁇ in the form of granule ⁇ which may be mixed with filler ⁇ ⁇ uch a ⁇ lacto ⁇ e, binder ⁇ such a ⁇ starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active compounds are preferably dis ⁇ olved or ⁇ u ⁇ pended in ⁇ uitable liquid ⁇ , ⁇ uch a ⁇ fatty oil ⁇ , or liquid paraffin.
- Po ⁇ ible pharmaceutical preparation ⁇ which can be u ⁇ ed rectally include, for example, ⁇ uppo ⁇ itories, which consist of a combination of one or more of the active compounds with a suppo ⁇ itory ba ⁇ e.
- Suitable ⁇ uppo ⁇ itory ba ⁇ es are, for example, natural or synthetic triglyceride ⁇ , or paraffin hydrocarbon ⁇ .
- Po ⁇ ible ba ⁇ e materials include, for example, liquid triglyceride ⁇ , polyethylene glycol ⁇ , or paraffin hydrocarbon ⁇ .
- Suitable formulation ⁇ for parenteral administration include aqueous solution ⁇ of the peptide ⁇ in water- ⁇ oluble form, for example, water-soluble salt ⁇ .
- ⁇ uspension ⁇ of the peptide ⁇ a ⁇ appropriate oily injection ⁇ uspen ⁇ ion ⁇ may be administered.
- Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglyceride ⁇ .
- Aqueou ⁇ injection ⁇ u ⁇ pensions may contain substances which increase the visco ⁇ ity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran.
- the ⁇ uspension may al ⁇ o contain stabilizers.
- the peptide ⁇ are formulated using conventional pharmaceutically acceptable parenteral vehicles for administration by injection. These vehicles are nontoxic and therapeutic, and a number of formulations are set forth in Remington's Pharmaceutical Sciences. (supra.. Nonlimiting examples of excipients are water, saline, Ringer' ⁇ ⁇ olution, dextrose solution and Hank's balanced salt solution.
- Formulation ⁇ according to the invention may also contain minor amounts of additives such as substance ⁇ that maintain isotonicity, physiological pH, and stability.
- the peptides of the invention are preferably formulated in purified form substantially free of aggregates and other protein materials, preferably at concentrations of about 1.0 ng/ml to 100 mg/ml.
- A2b and A2c helper T cell clones have been described previously (Holoshitz et al. , supra) . Briefly, a T cell line, A2, reactive to M. tuberculo ⁇ i ⁇ wa ⁇ first isolated from draining lymph nodes of Lewi ⁇ rat ⁇ immunized with ⁇ tuberculo ⁇ i ⁇ in incomplete Freund's adjuvant (IFA) . Subcloning of the A2 line revealed the presence of an arthritogenic T cell clone, A2b, and a protective T cell clone, A2c. Both clone ⁇ recognized the same epitope, contained in residues 180-188 of hsp 65.
- IFA incomplete Freund's adjuvant
- the T cell clone ⁇ were cyclically re ⁇ timulated for three day ⁇ with heat killed M. tuberculo ⁇ i ⁇ and propagated for one week in Iscove' ⁇ modification of Dulbecco' s Modified Eagle's Medium (Gibco) , supplemented with 10% fetal calf ⁇ erum (FCS) , 10% EL-4 ⁇ upernatant (containing variou ⁇ T cell growth factor ⁇ ) , 2 mM glutamine, antibiotics, and 1% nonessential amino acids.
- FCS fetal calf ⁇ erum
- EL-4 ⁇ upernatant containing variou ⁇ T cell growth factor ⁇
- MBP myelin basic protein
- helper T cell line ATL wa ⁇ i ⁇ olated from the popliteal lymph node ⁇ of a Lewis rat 10 days after hind footpad immunization with 100 ⁇ g/ml peptide A183 in CFA (containing 4 mg/ml of M. tuberculosi ⁇ (H37Ra) .
- T cell lines were cyclically restimulated in vitro for 3 or 4 day ⁇ with irradiated (3000 rad ⁇ ) thymocytes as APCs and 10 ⁇ g/ml heat-killed Mt in case of clone A2b, 10 ⁇ g/ml MBP in case of T cell line Zla or 10 ⁇ g/ml peptide A183 in case of T cell line ATL and propagated for 6 or 7 day ⁇ in I ⁇ cove's Modified Dulbecco ' ⁇ Medium (Gibco) , supplemented with 10% FCS, 10% EL-4 supernatant ⁇ (a ⁇ a source of IL-2) , 2 mM glutamine, 2-ME, antibiotics and 1% non-essential amino acids.
- the proliferative respon ⁇ e of T cell clones was assessed by measuring 3 H-thymidine incorporation into cells over the final 18-20 hours of culture.
- Cells (2 x 10 4 cells/well) were cultured for 4 days in flat-bottom 96-well microtiter plates in the presence of irradiated (1500 rads) syngeneic thymocyte ⁇ (1 x 10 6 cell ⁇ /well) a ⁇ antigen pre ⁇ enting cell ⁇ and variou ⁇ amount ⁇ of antigen.
- i ⁇ otope Following incorporation of the i ⁇ otope, cell ⁇ were harve ⁇ ted and counted using routine procedures.
- the competitor peptide wa ⁇ added to the culture containing the T cell ⁇ and irradiated thymocytes and responder cell ⁇ 1-2 hours before the addition of the ⁇ timulatory peptide 180-188.
- the single alanine sub ⁇ tituted peptide analog ⁇ derived from non peptide 180-188, the 180-188 amino acid ⁇ equence of the mycobacterial 65 kD protein, were synthesized with the PEPSCAN method (Geysen, H.M. et al. , Proc. Natl. Acad. Sci. USA, 1984, 11:3998; Proc. Natl.- Acad. Sci. USA 1985, £2 . :178)) and detached from their ⁇ olid ⁇ upports and used in T cell proliferation a ⁇ ays a ⁇ de ⁇ cribed previously (van der Zee et al. , supra) .
- the SMPS ⁇ et-up wa ⁇ developed u ⁇ ing a ⁇ tandard auto ⁇ ampler (Gil ⁇ on model 221) .
- SMPS automated simultaneous multiple peptide synthe ⁇ i ⁇
- Peptides were obtained a ⁇ C-terminal amide ⁇ from 7.5 mg re ⁇ in/peptide (0.21 meq/g, PAL TM re ⁇ in, Milligen) .
- the activitie ⁇ of in vitro defined non- inhibitory and inhibitory peptide ⁇ ⁇ ynthesized by the PEPSCAN or the SMPS method were confirmed with the alanine ⁇ ub ⁇ tituted peptides, A184, 1029 and A183, 1028 prepared by conventional solid phase synthesi ⁇ .
- PEPTIDE A183 INHIBITS PROLIFERATIVE RESPONSES IN VITRO OF T CELLS OF CLONES TO NATIVE PEPTIDE 180-188
- Proliferative re ⁇ pon ⁇ e ⁇ of the T cell clone ⁇ and the capacity of ⁇ ynthetic peptide ⁇ to compete with the native ⁇ timulatory peptide 180-188 were a ⁇ e ⁇ sed as described above.
- Figure 2 show ⁇ response of A2c cells to a suboptimal concentration of the native peptide 180-188 in the ab ⁇ ence or presence of alanine- ⁇ ub ⁇ tituted peptides.
- A181 was also inhibitory, although to a les ⁇ er extent.
- a peptide with an alanine ⁇ ubstitution at position 182 showed only slight inhibition.
- Peptides with substitution ⁇ at positions 180. 184, 185, or 186 failed to inhibit response ⁇ to the ⁇ timulatory peptide.
- inhibitory peptide ⁇ were tested in the presence of increasing concentrations of stimulatory peptide 180-188.
- the stimulatory 180- 188 peptide overcame inhibition in a dose-dependent manner. Therefore, the inhibition by the substituted peptides followed the rules of dose-dependent competition.
- respon ⁇ e ⁇ to the T cell itogen, concanavalin A (Con A) were not affected by the presence of alanine-sub ⁇ tituted peptides in the concentrations which could inhibit the 180-188 respon ⁇ e.
- Figure 4 ⁇ how ⁇ that, when the competitor peptides were added at the ⁇ ame time a ⁇ the stimulatory peptide (here at 0.1 ⁇ g/ml), without preincubation, A183 competed for recognition by A2b cell ⁇ , but A181 did not.
- Figure 5 ⁇ how ⁇ a distinct set of experiments which demon ⁇ trate the do ⁇ e-dependency of the inhibitory activitie ⁇ of A183.
- A2b cells were incubated with APC and a fixed concentration of A183 (10 ⁇ g/ml) . After 1-2 hours of preincubation, increa ⁇ ing concentration ⁇ , from 0.1 - 10 ⁇ g/ml of stimulatory antigen ⁇ were added (Figure 5a: peptide 180-188; Figure 5b: hsp 65; Figure 5c: M. tuberculosi ⁇ ) .
- di ⁇ ea ⁇ e can be induced by immunization with the ba ⁇ ic protein of myelin (MBP) or by inoculation of MBP-reactive T cell line ⁇ , ⁇ uch a ⁇ Zla (Ben- Nun, A. et al. , J. Immunol. 129: 303 (1982)) .
- Figure 6 how ⁇ that proliferative re ⁇ ponses of Zla to MBP are inhibited by A183.
- the Zla cell line is known to recognize the amino acid sequence of re ⁇ idues 68-88 of MBP, which bears no ⁇ equence or structural similarity to residue ⁇ 180-188 Of hsp 65.
- A183 seems to inhibit respon ⁇ e ⁇ of both the arthriti ⁇ - ⁇ pecific T cell clone ⁇ and an encephaliti ⁇ - specific T cell line by competing for binding at the level MHC cla ⁇ II molecule ⁇ (Rt-1 B locu ⁇ product ⁇ ) involved in antigen presentation.
- Lewis rats were immunized ⁇ ubcutaneou ⁇ ly (SC) in their hind footpads with A183 (500 ⁇ g/rat) in IFA, or with IFA alone. Sixteen days later, rats were immunized intracutaneously at the ba ⁇ e of the tail with 1 mg of heat- killed M. tuberculosis in IFA. Eleven days later, the popliteal lymph nodes (LN) were removed and the T cells were tested in a ⁇ tandard proliferation a ⁇ say using 2 x 10 5 cells/well and variou ⁇ concentration ⁇ of A183, ranging from 1 - 50 ⁇ g/ml. 3 H-thymidine incorporation wa ⁇ measured after 4 day ⁇ of culture.
- SC ⁇ ubcutaneou ⁇ ly
- Figure 7 show ⁇ proliferative re ⁇ ponse ⁇ of immune or control LN cell ⁇ to variou ⁇ do ⁇ e ⁇ of A183, indicating that, under appropriate circum ⁇ tances, A183 can function as an immunogenic peptide.
- A183 REDUCES THE SEVERITY OF M. TUBERCULOSIS-INDUCED ARTHRITIS The re ⁇ pon ⁇ e to hsp 65 residue ⁇ 180-188 by the A2b T cell clone i ⁇ dominant in adjuvant arthriti ⁇ , and the re ⁇ pon ⁇ e to MBP by the T cell clone Zla i ⁇ dominant in experimental allergic encephalomyeliti ⁇ . Since A183 inhibited these clonal T cell reactivities in vitro, the in vivo effects of A183 admini ⁇ tration at the time of di ⁇ ease induction were investigated.
- Figure 8 shows that the concomitant administration of A183 with M. tuberculosis caused a significant reduction in the severity of arthritis (p ⁇ 0.02).
- the disease developing in A183-treated rats was very mild and did not cause irreversible joint damage (average maximum disease score of 4) .
- Animals which did not receive A183 developed much more severe disease with irreversibly ankylosed joints.
- EAE was induced in Lewi ⁇ rats by injecting 0.1 ml of a 1:1 emul ⁇ ion of MBP in ⁇ aline and complete Freund' ⁇ adjuvant (containing 4 mg/ml M. tuberculo ⁇ i ⁇ ) in both hind footpad ⁇ .
- Clinical ⁇ ign ⁇ of di ⁇ ea ⁇ e were monitored daily, and rated on a ⁇ cale of 0 to 4: 0, no ⁇ ign ⁇ ; 0.5, lethargy and weight lo ⁇ ; 1, limp tail; 2, hind leg weakness?
- the A183 peptide appears to be capable of interacting with different MHC products, both rat and human. A183 not only inhibits antigen specific T cell recognition in both specie ⁇ , but in addition, it effectively interferes with the m. vivo generation of autoimmune effector T cells, as shown in adjuvant arthriti ⁇ and allergic encephalomyeliti ⁇ experiment ⁇ , above.
- a ⁇ ingle ⁇ ub ⁇ titution network of peptide 180-188 wa ⁇ prepared. In thi ⁇ network every re ⁇ idue of the nonapeptide wa ⁇ replaced by all 19 other po ⁇ ible amino acid ⁇ (See Figure 1) .
- Sub ⁇ titution peptide ⁇ that induced high proliferative T cell re ⁇ pon ⁇ es were: position 180 T- ->S; position 181 F—>L; and position 186 E—>D or E—>Q.
- Peptides having the following substitution ⁇ were al ⁇ o stimulatory for both T cell clones: position 180 T—>D or — >K; position 182 F—>I; position 186 E—>H.
- the degree of proliferative responses found in the presence of the latter ⁇ ub ⁇ titutions peptides was clearly inferior to those obtained with native peptide 180-188.
- Sub ⁇ titution peptides with two or three replacements were found to be non-stimulatory. Based upon the result ⁇ obtained with the ⁇ ingle ⁇ ub ⁇ titution network, the better ⁇ timulatory sub ⁇ titution ⁇ , po ⁇ ition 180 T—>S, po ⁇ ition 181 F—>L, and po ⁇ ition 186 E—>D were selected for ⁇ ynthe ⁇ is of combined substitution peptides. Proliferative re ⁇ pon ⁇ es of the A2b and A2c T cell clones to the combined-substitution peptide ⁇ were determined.
- a ⁇ can be ⁇ een from the re ⁇ ult ⁇ for clone A2b, ⁇ hown in the lower half of Table 5, none of the peptide ⁇ with two or three combined ⁇ ub ⁇ titution ⁇ at po ⁇ ition ⁇ 180, 181, and 186 was stimulatory.
- T cell clone A2b responded to the native peptide 180-188 and to the alanine- ⁇ ub ⁇ tituted peptides A187 and A188.
- Figure 11 shows that T cell line Zla responded not only to the native MBP peptide 1020 but also to the alanine-sub ⁇ tituted peptide ⁇ 1021, 1024, 1026, 1030, and 1032, and a very modest response to peptide 1031 was noted.
- Peptide 1026 induced a larger proliferative re ⁇ pon ⁇ e than did peptide 1020.
- inhibitory peptide A183 or 1028 When a fixed dose of inhibitory peptide A183 or 1028 was tested in the pre ⁇ ence of increasing concentrations of stimulatory peptide 180-188, the inhibition could be overcome in a dose-dependent manner, arguing against any non-specific toxic effects of the inhibitory peptides on the T cells. Furthermore, both A183 and 1028 inhibited the proliferative response of Zla cells to either MBP or peptide 1020, whereas peptide ⁇ A184 and 1029 did not inhibit.
- peptide A183 and 1028 were selected for testing in the adjuvant arthriti ⁇ and EAE di ⁇ ease model ⁇ .
- peptide A184 and 1029 were used as control ⁇ .
- Rat ⁇ were ob ⁇ erved daily and graded on a four-point ⁇ cale. k Number with di ⁇ ea ⁇ e/number te ⁇ ted. c Average day of disease onset of those animals that develope disease (1SD) .
- di ⁇ ea ⁇ e can be induced by a well-defined MBP-related peptide
- the di ⁇ ea ⁇ e-inducing antigen for adjuvant arthritis is whole heat-killed
- rats were immunized at day 0 with Mt (250 ⁇ g) in IFA emul ⁇ ified with PBS or A183 (250 ⁇ g) or A184 (250 ⁇ g) in PBS.
- Rat ⁇ were immunized with 100 ⁇ g A183 in CFA in the hind footpads and, 10 days later, popliteal lymph node cell ⁇ were obtained and ⁇ timulated in vitro with A183 (10 ⁇ g/ml) for 4 day ⁇ .
- the cell ⁇ were then expanded for 1 week i IL2-containing medium and restimulated for 4 day ⁇ by A183 (10 ⁇ g/ml) in the pre ⁇ ence of ⁇ yngeneic irradiated thymocyte ⁇ a ⁇ antigen pre ⁇ enting cell ⁇ .
- Table 8 ⁇ how ⁇ the antigen ⁇ pecificity of a CD4 + T cell line, de ⁇ ignated ATL, obtained after 6 restimulation cycles in vitro.
- DDA dimethyl - dioctadecylammonium bromide
- a di ⁇ ea ⁇ e induced by a highly complex antigen, whole mycobacteria, disea ⁇ e inhibition by co-immunization with a competitor peptide apparently involve ⁇ the ⁇ ynergistic effect of competition for MHC binding between competitor and disea ⁇ e- eliciting epitope ⁇ , a ⁇ well a ⁇ the concomitant induction of a regulatory (protective) immune re ⁇ pon ⁇ e.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57850690A | 1990-09-06 | 1990-09-06 | |
US578506 | 1990-09-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0503055A1 true EP0503055A1 (de) | 1992-09-16 |
EP0503055A4 EP0503055A4 (de) | 1994-02-16 |
Family
ID=24313172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP91918631A Withdrawn EP0503055A1 (de) | 1990-09-06 | 1991-09-05 | Inhibitor der lymphozyten-antwort und immunverwandter krankheiten |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0503055A1 (de) |
JP (1) | JPH05507501A (de) |
AU (1) | AU650065B2 (de) |
CA (1) | CA2071896A1 (de) |
IL (1) | IL99429A0 (de) |
NZ (1) | NZ239699A (de) |
WO (1) | WO1992004049A1 (de) |
ZA (1) | ZA917097B (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09509135A (ja) * | 1993-06-02 | 1997-09-16 | ティーヴィダブリュー テレソン インスティテュート フォー チャイルド ヘルス リサーチ | 免疫寛容の誘導における利用のためのクリプティックペプチド |
CA2185826C (en) * | 1994-03-21 | 2007-06-19 | Stephen Mark Anderton | Peptide fragments of microbial stress proteins and pharmaceutical composition made thereof for the treatment and prevention of inflammatory diseases |
GB9419553D0 (en) * | 1994-09-27 | 1994-11-16 | Univ Bristol | Polypeptides and their use in the treatment of auto-immune disease |
IT1271074B (it) * | 1994-11-21 | 1997-05-26 | Italfarmaco Spa | Peptidi ad attivita' antiinfiammatoria |
US6592877B1 (en) | 1995-09-01 | 2003-07-15 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
US6290969B1 (en) | 1995-09-01 | 2001-09-18 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
US6338852B1 (en) | 1995-09-01 | 2002-01-15 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
US6458366B1 (en) | 1995-09-01 | 2002-10-01 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
US5993803A (en) * | 1996-08-30 | 1999-11-30 | Yeda Research And Development Co., Ltd. | Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity |
WO1998032451A1 (en) * | 1997-01-24 | 1998-07-30 | Autoimmune, Inc. | Treatment of autoimmune disease using tolerization in combination with methotrexate |
US6465633B1 (en) | 1998-12-24 | 2002-10-15 | Corixa Corporation | Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis |
EP2157101B1 (de) | 2002-01-31 | 2014-09-24 | Andromeda Bio Tech Ltd. | HSP-Peptide und Analoga zur Modulation von Immunantworten mittels antigenpräsentierenden Zellen |
EP2301566B1 (de) | 2002-05-21 | 2013-07-03 | Irun R. Cohen | DNA-Vakzinen, die für Hitzeschockprotein kodieren |
EP1835933A4 (de) | 2005-01-04 | 2015-01-07 | Yeda Res & Dev | Hsp60, hsp60-peptide und t-zellen-impfstoffe zur immunmodulation |
-
1991
- 1991-09-05 JP JP91517849A patent/JPH05507501A/ja active Pending
- 1991-09-05 EP EP91918631A patent/EP0503055A1/de not_active Withdrawn
- 1991-09-05 WO PCT/US1991/006434 patent/WO1992004049A1/en not_active Application Discontinuation
- 1991-09-05 AU AU87559/91A patent/AU650065B2/en not_active Expired - Fee Related
- 1991-09-05 CA CA002071896A patent/CA2071896A1/en not_active Abandoned
- 1991-09-06 IL IL99429A patent/IL99429A0/xx unknown
- 1991-09-06 ZA ZA917097A patent/ZA917097B/xx unknown
- 1991-09-06 NZ NZ239699A patent/NZ239699A/en unknown
Non-Patent Citations (5)
Title |
---|
BIOLOGICAL CHEMISTRY HOPPE-SEYLER vol. 367 , 1986 , BERLIN,DE pages 825 - 834 SCHAICH ET AL 'CLONED PROTEOLIPID PROTEIN AND MYELIN BASIC PROTEIN CDNA' * |
No further relevant documents disclosed * |
See also references of WO9204049A1 * |
THE BIOCHEMICAL JOURNAL vol. 141 , 1974 , LONDON,GB pages 243 - 255 DUNKLEY ET AL 'AMINO ACID SEQUENCE OF THE SMALLER BASIC PROTEIN FROM RAT BRAIN MYELIN' * |
THE JOURNAL OF IMMUNOLOGY vol. 129 , 1982 , BALTIMORE,USA pages 303 - 308 BEN-NUN ET AL 'EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS (EAE) MEDIATED BY T CELL LINES:PROCESS OF SELECTION OF LINES AND CHARACTERIZATION OF THE CELLS' * |
Also Published As
Publication number | Publication date |
---|---|
JPH05507501A (ja) | 1993-10-28 |
IL99429A0 (en) | 1992-08-18 |
ZA917097B (en) | 1992-09-30 |
WO1992004049A1 (en) | 1992-03-19 |
AU8755991A (en) | 1992-03-30 |
NZ239699A (en) | 1993-11-25 |
EP0503055A4 (de) | 1994-02-16 |
CA2071896A1 (en) | 1992-03-07 |
AU650065B2 (en) | 1994-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3072330B2 (ja) | 自己免疫疾患および悪性疾患の治療のためのt細胞リセプターペプチド | |
Racke et al. | Copolymer-1-induced inhibition of antigen-specific T cell activation: interference with antigen presentation | |
Gaston et al. | Recognition of a mycobacteria-specific epitope in the 65-kD heat-shock protein by synovial fluid-derived T cell clones. | |
Sakai et al. | Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins. | |
DE69326064T2 (de) | Peptide des menschlichen Proteins P53 zum Gebrauch in menschlichen-zytotoxischen-T-Zell-Antwort-induzierenden Kompositionen sowie menschliche P53-Protein-spezifische T-Lymphocyten | |
JP2635444B2 (ja) | 自己抗体の経口投与による自己免疫性疾患の治療 | |
AU775073B2 (en) | Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD | |
JP5587586B2 (ja) | 多様な治療様式のための主成分としての選択的スプライスフォーム | |
Wraith et al. | Cross-reactive antigen recognition by an encephalitogenic T cell receptor. Implications for T cell biology and autoimmunity. | |
EP0503055A1 (de) | Inhibitor der lymphozyten-antwort und immunverwandter krankheiten | |
JPH0272197A (ja) | 自己免疫疾患の処置としての抗―t細胞レセプター決定基 | |
IE912701A1 (en) | Novel immunosuppressant peptides | |
Yang et al. | Prevention of adjuvant arthritis in rats by a nonapeptide from the 65-kD mycobacterial heat-shock protein | |
JPH10509714A (ja) | ヒトミエリン塩基性タンパク質の91位におけるペプチドアナログを用いる多発性硬化症の処置方法 | |
CA2110055C (en) | T cell receptor peptides as therapeutics for immune-related disease | |
MXPA04007510A (es) | Peptidos tolerogenicos de la proteina basica de mielina. | |
US5961977A (en) | Method of treating or preventing autoimmune uveoretinitis in mammals | |
HU219306B (en) | T-cell-suppressive peptide fragments of human myelin basic protein (hmbp) and pharmaceutical compositions containing them | |
Vandenbark et al. | Determinants of human myelin basic protein that induce encephalitogenic T cells in Lewis rats. | |
JP3875730B2 (ja) | 自己免疫疾患の予防治療剤 | |
US5000952A (en) | Polypeptide pertussis toxin vaccine | |
Myers et al. | PART III. Autoimmunity An Altered Peptide Ligand of Type II Collagen Suppresses Autoimmune Arthritis | |
JP2007507541A (ja) | 修飾型の規則正しいペプチドによる脱髄性自己免疫性疾患の治療方法 | |
JPH11511129A (ja) | H−y抗原 | |
JP2010235607A (ja) | 自己免疫疾患の診断薬と治療薬となるペプチド類 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19920505 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
RHK1 | Main classification (correction) |
Ipc: C07K 7/06 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19931227 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19960401 |